% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • bubbarayjr bubbarayjr Nov 27, 2012 10:34 PM Flag

    News: Insurers, Obamacare to COVER Obesity drugs. Market estimated at $60B or higher.

    More insurers, ObamaCare to cover obesity drugs made by Arena, Vivus

    Important policy shifts at the federal level bode well for much broader health insurance coverage of prescriptions for obesity drugs made by Vivus, Inc., and Arena Pharmaceuticals. Image: Vivus, Inc.
    By Rex Graham

    This season of pumpkin pie, mashed potatoes and rising obesity rates is a perfect time to talk turkey about the overly bearish sales estimates of Belviq and Qsymia, the obesity drugs approved by the FDA this summer.

    The oft-cited $1 billion-a-year combined estimated sales for Qsymia, which is made by Vivus, Inc. (VVUS), and Belviq, made by Arena Pharmaceuticals (ARNA), should be revised upward. Why? It’s not just because of Aetna’s Nov. 20 revision to include Qsymia and Belviq “as medically necessary weight reduction medications” for its 37.3 million covered health plan members.

    Two important policy shifts at the federal level – by the Centers for Medicare & Medicaid Services and the U.S. Preventive Services Task Force – also bode well for much broader coverage of weight loss prescription medicines. The shift is a logical way to cut massive health costs caused by obesity. The trajectory of policy shifts is leading experts to predict that Qsymia and Belviq will soon become covered by all private and public health insurers, including Medicare, the federal health plan for Americans aged 65 and older and younger people with disabilities, and Medicaid, the federal-state health program for low-income individuals and families.

    Even the Mayo Clinic informs patients visiting its website that Qsymia and Belviq are “prescription weight-loss medications your doctor may prescribe.” Estimates of the market in the U.S. alone for obesity drugs are as high as $60 billion a year, but nobody knows for sure. Consider this: the market capitalization of Vivus currently at $1.12 billion and Arena’s market cap at $2.03 billion. Even if the obesity drug market’s eventual size is one-tenth of the highest current estimate, both companies are grossly undervalued.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • vir249 Dec 24, 2012 1:16 PM Flag

      Qsymia is a laggard drug..Don't even mention it with Belviq. Belviq will be 30 bil. drugs over its patent span...

      Sentiment: Strong Buy

    • VA will announce during comment period

    • johnrambo777 Nov 28, 2012 7:41 AM Flag about a bad short!!

      Sentiment: Strong Buy

    • Interpretation: Taxpayers to cover Obesity drugs (like everything else FREE FOR ALL UNDER OBAMA!!) Ever heard the ole adage 'there's no free lunch?' So just how good will our piles of Arena $$$$ be once the stock hits it's stride, when in reality a USA BUCK $$$ is hardly worth the paper it is written on after 100 years of the DEM FED RESERVE BANK debt leveraging our currency to it's ZERO intrinsic value of today. Yep FREE EVERYTHING FOR ALL that's what you D_U_M_M_I_E_S voted for again and now Sandra FLUCK is out flaunting HER FREEBIE R_U_B_B_E_R_S such that we will finally realize just how the dems FLUCKED US ALL!

    • Federal Register
      Vol. 77, No. 228
      Tuesday, November 27, 2012

      Proclamation 8907 of November 20, 2012

      National Child’s Day, 2012

      By the President of the United States of America

      Quote Administration
      is striving to fulfill ours through efforts like First Lady Michelle Obama’s Let’s Move! initiative, which aims to solve the problem of childhood obesity within a generation, and the Affordable Care Act, which has expanded preventive services for children and ensured health coverage for millions of young adults...... hereby proclaim November 20, 2012, as National Child’s Day.....


      " Affordable Care Act, which has expanded preventive services for children and ensured health coverage for millions of young adults "

      Sentiment: Strong Buy

1.60-0.03(-1.84%)4:00 PMEDT